Skip to content
Back to search results

Brief Addiction Monitor (BAM)

Introduced by
Cacciola, Alterman, Drapkin, Valadez
Year
2013
Type
Self-report
Family
substance-use-monitoring
Font size

What does it do?

The BAM is a 17-item self-report instrument designed to provide rapid, multimodal assessment of substance use, craving, risk factors, protective factors, and psychosocial functioning in individuals receiving addiction treatment.

Developed by Cacciola and colleagues in 2013, it serves as an efficient outcome monitoring tool for tracking treatment progress, identifying relapse warning signs, and guiding therapeutic adjustments. The BAM is useful in treatment settings where frequent assessment of multiple domains is needed to optimize care.

The intuition behind the method

The BAM operationalizes the biopsychosocial model of addiction by measuring not only substance use behavior but also the psychological (craving, mood), social (support, stressors), and environmental factors that influence recovery. Rather than focusing solely on abstinence, the BAM captures the complex interplay of risk and protective factors that determine relapse vulnerability. This approach aligns with contemporary recovery science, which recognizes that sustained recovery depends on addressing multiple life domains and building resilience, not just eliminating drug use.

History

The BAM was developed by Cacciola and colleagues at the Treatment Research Institute at the University of Pennsylvania and published in the Journal of Substance Abuse Treatment in 2013. The instrument was designed to meet the need for a brief, practical progress monitoring tool that could be administered frequently in busy treatment settings without undue burden. The BAM was derived from longer, more comprehensive addiction assessments (e.g., the Addiction Severity Index) and refined to focus on the most clinically relevant items for outcome monitoring. It has been adopted in numerous treatment programs and is increasingly used in routine outcome monitoring and quality improvement initiatives.

When to use it

The BAM is appropriate for use during addiction treatment to monitor outcomes at regular intervals (weekly to monthly depending on treatment intensity). It is particularly useful in intensive outpatient programs (IOP), residential treatment, and medication-assisted treatment (MAT) settings where frequent monitoring is feasible and necessary. The BAM serves as a progress monitoring tool rather than a screening instrument; it should be used in individuals already engaged in treatment. It is less suitable for one-time assessment or diagnosis; use DUDIT, SADQ, or CUDIT-R for initial screening.

Limitations and considerations

  • Not designed as a screening or diagnostic instrument; intended for use in individuals already identified as substance users
  • Depends on self-report and may be subject to underreporting, particularly in legal or institutional contexts where honesty carries risk
  • Multimodal scoring produces domain-specific rather than single composite scores, requiring interpretation across multiple dimensions
  • Norms and cutoff scores are less established than for longer, extensively validated instruments

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Multimodal assessment capturing substance use, craving, risk factors, protective factors, and functioning in a brief instrument
  • Designed specifically for outcome monitoring during treatment, with sensitivity to detect within-person changes over time
  • Includes both deficit (risk factors) and asset (protective factors) domains, aligning with strengths-based and resilience-focused care approaches
  • Brief administration time (5–10 minutes) makes it feasible for frequent progress monitoring during intensive treatment
  • Provides actionable clinical data across multiple domains to guide treatment adjustments and relapse prevention

Applications

  • Weekly or biweekly progress monitoring during intensive outpatient or residential addiction treatment to track substance use reduction and recovery indicators
  • Medication-assisted treatment (MAT) outcome monitoring to assess the effectiveness of opioid or alcohol medications and identify barriers to treatment engagement
  • Identification of early warning signs of relapse (increasing use, rising craving, declining protective factors) to enable timely therapeutic intervention
  • Treatment planning and adjustment; BAM data inform decisions about step-down or intensification of care level
  • Research and quality improvement studies investigating treatment outcomes, predictors of recovery, and effectiveness of specific interventions

How it works

How it works

1

The BAM comprises 17 items covering five major domains: (1) Substance use—days of use in the past 30 days across the primary substance and other drugs; (2) Craving—intensity of urges to use; (3) Risk factors—psychosocial stressors, negative mood, sleep disturbance, pain; (4) Protective factors—peer support, family support, coping strategies, medication adherence; and (5) Overall functioning—employment, legal involvement, and psychosocial well-being. Items use variable response formats (e.g., frequency scales, severity ratings, yes/no responses). The BAM is self-administered or can be conducted in brief interview format and takes approximately 5–10 minutes.

Formula
17 items assessing substance use frequency, craving, risk factors, protective factors, and psychosocial functioning across the past 30 days
2

Scoring yields domain-specific scores rather than a single total score. Substance Use is measured as the number of days of use in the past 30 days (0–30); Craving is rated on a 0–10 intensity scale; Risk Factors and Protective Factors are scored on frequency or presence/absence scales. The instrument provides a domain profile rather than a composite severity score, allowing clinicians to track patterns across multiple domains. Scores are typically charted over time to monitor treatment response and identify emerging problems.

Formula
Generate scores across domains: Substance Use (days of use), Craving, Risk Factors (psychosocial stressors), Protective Factors (social support, coping), and Overall Functioning. Item responses scale varies by domain.
3

Higher substance use days and craving intensity indicate greater active use and relapse risk; interventions should intensify during these periods. Lower protective factors (reduced support, coping difficulties) indicate heightened vulnerability. The BAM is interpreted as a monitoring tool tracking changes over time within individuals rather than normative comparisons. Increasing use or craving despite treatment may indicate need for treatment intensification, medication adjustment, or psychiatric intervention. Declining use with stable or increasing protective factors indicates treatment progress and resilience building.

Formula
Higher use and craving scores indicate greater substance use severity and relapse risk. Lower protective factors indicate reduced resilience. Scores guide treatment intensity adjustments and relapse prevention planning.

Common pitfalls

  • Using BAM alone without clinical interview and collateral information; self-reported use and craving should be corroborated by objective markers (urinalysis, clinical observation)
  • Overinterpreting single BAM assessments; the BAM is most useful when administered serially to track within-person change
  • Failing to follow up on rising risk factors or declining protective factors with therapeutic intervention; BAM data should drive treatment decisions
  • Neglecting to assess medical, psychiatric, and psychosocial comorbidities that may influence BAM scores and treatment effectiveness

Frequently asked questions

How often should the BAM be administered?

The BAM is designed for frequent administration (weekly to monthly) during active treatment. Frequency depends on treatment setting: intensive outpatient programs may administer weekly; standard outpatient may administer monthly. Serial administration is more informative than single assessments.

What does a high craving score mean?

A high craving score (e.g., 7–10 on a 0–10 scale) indicates strong urges to use substances. While craving is common during recovery and does not predict relapse with certainty, persistently high craving despite treatment may indicate need for medication adjustment, intensified coping skill training, or assessment for psychiatric comorbidity.

Can the BAM be used to diagnose addiction?

No. The BAM is a progress monitoring tool for individuals in treatment, not a diagnostic instrument. Use DUDIT, SADQ, CUDIT-R, or DSM-5 criteria-based assessment for diagnostic purposes.

What if BAM scores show increasing use despite treatment attendance?

Increasing use (or craving) despite treatment engagement warrants clinical investigation and potential treatment modifications. Consider psychiatric comorbidity, inadequate medication dosing (if applicable), social stressors, trauma history, or need for more intensive psychosocial intervention. Collateral information (urinalysis, family report) should verify self-reported use.

How do I interpret declining protective factors on the BAM?

Declining protective factors (reduced support, weakened coping) indicate reduced resilience and heightened relapse risk. Therapeutic response should focus on rebuilding support networks, skill training, and addressing barriers to engagement (e.g., trauma, stigma, loss).

Is the BAM suitable for use with adolescent substance users?

The BAM was developed and validated in adult populations. Its applicability to adolescents requires adaptation and validation in age-appropriate language and item relevance. Clinicians using BAM with adolescents should consider developmental appropriateness and supplement with structured adolescent-specific assessments.

Related methods

Sources

  1. Cacciola, J. S., Alterman, A. I., Drapkin, M. L., & Valadez, C. (2013). Development and initial validation of the Brief Addiction Monitor (BAM). Journal of Substance Abuse Treatment, 44(3), 256–263.

    Open DOI reference
    Copied.